

Biocon SEZ, Biocon Park, Plot No. 2 &
3, Bommasandra Industrial Area, IV
Phase, Jigani Link Road, Bengaluru
560 099, Karnataka, India

T +91 80 6891 8000

F +91 80 6891 8808

CIN: L85110KA1993PLC01493

www.syngeneintl.com

July 23, 2020

To, The Manager Listing BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager Listing National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Dear Sir/Madam,

Subject: Change in the Directorate

Pursuant to the provisions of regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you the following appointments/re-appointments of the directors passed by the shareholders at the 27th Annual General Meeting held on July 22, 2020:

1. Regularization of appointment of Ms. Kiran Mazumdar Shaw (DIN: 00347229) as Director liable to retire by rotation.
2. Appointment of Ms. Vinita Bali as the Independent Director on the Board of Directors of the Company, for a second term of five years from the conclusion of 27th Annual General Meeting of the Company held on July 22, 2020 , till the conclusion of the 32nd Annual General Meeting proposed to be held in 2025.
3. Appointment of Mr. Vijay Kuchroo as the Independent Director on the Board of Directors of the Company, for a second term of five years from the conclusion of 27th Annual General Meeting of the Company held on July 22, 2020 , till the conclusion of the 32nd Annual General Meeting proposed to be held in 2025.
4. Regularization of appointment of Mrs. Sharmila Abhay Karve (DIN: 05018751) as an Independent Director of the Company who was appointed on July 24, 2019 as an Additional Director.
5. Regularization of appointment of Dr. Carl Peter Decicco (DIN: 08576667) as an Independent Director of the Company who was appointed on July 24, 2019.
6. Appointment of Mr. Jonathan Hunt as the Chief Executive Officer and Managing Director of the Company, not liable to retire by rotation, for a period of five years commencing from April 1, 2020 and on such remuneration as approved by the shareholders at the 27th Annual General Meeting

The brief profiles of Ms. Kiran Mazumdar Shaw, Ms. Vinita Bali, Mr. Vijay Kuchroo, Mrs. Sharmila Abhay Karve, Dr. Carl Peter Decicco and Mr. Jonathan Hunt are enclosed.

This intimation will also be available on website of the Company www.syngeneintl.com.



This is for your information and record.

Thanking You,

Yours faithfully,

For **SYNGENE INTERNATIONAL LIMITED**

Priyadarshini Mahapatra

Company Secretary & Compliance Officer

1. Ms. Kiran Mazumdar Shaw - Brief Profile



Kiran Mazumdar Shaw is a first-generation entrepreneur with over 45 years of experience in the field of biotechnology. She is a recipient of 'Padma Shri' and the 'Padma Bhushan' awards. She was also conferred with the highest French distinction – Chevalier de l'Ordre National de la Légion D'Honneur (Knight of the Legion of Honour) in 2016. She is ranked #1 in the Business Captains category in Global 'Medicine Maker Power List'

2018. She was honoured with Order of Australia, Australia's highest civilian award and was named EY Entrepreneur of the year for India in 2019. She is also the Chairperson of Biocon Limited, Independent Director on the Board of Infosys, United Breweries Ltd and Narayana Hrudayalaya

Ms. Kiran Mazumdar Shaw is not related to any of the directors of the Company except to Mr. John Shaw as his spouse and Dr. Catherine Rosenberg as Sister-in-Law. She has not been debarred from holding the office of director by virtue of any SEBI order or any other such authority.

2. Ms. Vinita Bali - Brief Profile



Vinita Bali is a global business leader with extensive experience in leading and transforming large companies both in India and overseas. She served as Chief Executive Officer/ MD of Britannia Industries from 2005 to 2014. Prior to that, she worked with eminent multinationals like The Coca-Cola Company and Cadbury Schweppes Plc in a variety of marketing, general management and chief executive roles in the UK, Nigeria, South Africa, USA and Chile. At present Ms. Bali is a Non-Executive Director on the global

boards of Smith & Nephew Plc, Bunge Limited, Cognizant Technology Solutions and CRISIL Ltd in India. At Syngene, Vinita is a member of the Audit Committee, the Corporate Social Responsibility Committee and the Risk Management Committee and the Chairperson of the Nomination and Remuneration Committee.

Ms. Vinita Bali is not related to any of the directors of the Company. She has not been debarred from holding the office of director by virtue of any SEBI order or any other such authority.

3. Mr. Vijay Kuchroo - Brief Profile



Dr Kuchroo has a doctorate in Pathology from the University of Queensland, Australia. He is also the Samuel L. Wasserstrom Professor of Neurology at the Harvard Medical School, United States, Senior scientist at the Brigham and Women's Hospital and Institute Member at the Broad Institute of MIT and Harvard. Dr Kuchroo has won many awards for the discovery of TIM-3 "checkpoint" molecules for cancer

immunotherapy and Th17 cells in induction of autoimmunity. Dr Kuchroo holds 25 patents and has published over 325 research papers in immunology. He is a Member of the scientific advisory boards of leading pharmaceutical companies including Pfizer, Sanofi and GSK. He founded five different biotech companies including CoStim Pharmaceuticals and Tempero Pharmaceuticals. At Syngene, Dr Vijay Kuchroo is a member of the Nomination and Remuneration Committee and the Corporate Social Responsibility Committee.

Dr. Kuchroo is not related to any of the directors of the Company. He has not been debarred from holding the office of director by virtue of any SEBI order or any other such authority

4. Mrs. Sharmila Abhay Karve - Brief Profile



Sharmila Abhay Karve is a Fellow member of the Institute of Chartered Accountants of India. She retired as audit partner from Price Waterhouse in June 2019. During her tenure in Price Waterhouse, she was an engagement partner with various large and prestigious Indian and multinational clients. She was appointed as the Chief Ethics Officer. In 2009, she was appointed as the Assurance Leader of the firm and was elevated to the role of Assurance Risk & Quality Leader in April 2012. In her last role as Global Diversity Leader since December

2016, Ms. Karve focused her efforts on bringing more diversity throughout the PwC network. At Syngene, Ms. Sharmila Abhay Karve is a member of the Audit Committee and Risk Management Committee and Chairperson of the Stakeholders Relationship Committee

Ms. Karve is not related to any of the directors of the Company. He has not been debarred from holding the office of director by virtue of any SEBI order or any other such authority.

5. Dr. Carl Peter Decicco – Brief Profile



Dr Carl Peter Decicco, Ph.D., serves as the Chief Scientific Officer in Foghorn Therapeutics. Prior to joining Foghorn Therapeutics in 2018, he served as the Head of Discovery at Bristol-Myers Squibb (BMS). He also serves as a Member of the Advisory Committee at Allied-Bristol Life Sciences, LLC. He completed post-doctoral studies with Professor EJ Corey at Harvard University, was a teaching fellow at the University of British Columbia and obtained his Ph.D. with Professor Gordon Lange in Organic Chemistry from the Guelph-Waterloo Center in Ontario, Canada. At Syngene, he is a member of the Nomination and Remuneration Committee.

Dr Carl Peter Decicco is not related to any of the directors of the Company. He has not been debarred from holding the office of director by virtue of any SEBI order or any other such authority.

6. Mr. Jonathan Hunt -Brief Profile



Jonathan Hunt has an MBA from Durham University, United Kingdom, with over 30 years of experience in the global biopharmaceuticals industry. At Syngene, he is responsible for leading the Company's business operations and steering its investments in developing and strengthening its capabilities and capacity. Prior to joining Syngene, he held various leadership positions at AstraZeneca for over a decade, including President and Director of AstraZeneca, Austria, and President and Chief Operating Officer (COO), AstraZeneca, India. At Syngene, Jonathan Hunt is a member of the Stakeholders Relationship Committee and the Risk Management Committee.

Mr. Jonathan Hunt is not related to any of the directors of the Company. He has not been debarred from holding the office of director by virtue of any SEBI order or any other such authority.